Scroll

nabumetone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1863	42924-53-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nabumetone nabucox nabumeton nabuton	A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS. Molecular weight: 228.29 Formula: C15H16O2 CLOGP: 2.98 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 26.30 ALOGS: -5.07 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nabumetone
nabucox
nabumeton
nabuton

A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.

Molecular weight: 228.29
Formula: C15H16O2
CLOGP: 2.98
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 26.30
ALOGS: -5.07
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.02 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	0 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	125.15 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	35 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Dec. 24, 1991	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	91.31	13.38	170	9702	250840	50344412
Retinopathy	35.71	13.38	15	9857	2697	50592555
Periarticular disorder	25.47	13.38	5	9867	53	50595199
Depression	22.34	13.38	77	9795	165346	50429906
Rubella	20.41	13.38	5	9867	155	50595097
Emotional distress	19.57	13.38	26	9846	28637	50566615
Cerebrovascular accident	18.31	13.38	50	9822	94630	50500622
Off label use	18.31	13.38	41	9831	474385	50120867
Systemic lupus erythematosus	17.82	13.38	3	9869	140619	50454633
Injury	17.51	13.38	33	9839	48892	50546360
Gastrooesophageal reflux disease	17.50	13.38	43	9829	76385	50518867
Anxiety	16.88	13.38	74	9798	177532	50417720
Hypersensitivity myocarditis	16.27	13.38	3	9869	22	50595230

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Splenic embolism	44.66	17.55	9	3897	167	29570454
Sideroblastic anaemia	42.74	17.55	9	3897	209	29570412
Vitamin B1 decreased	41.30	17.55	9	3897	247	29570374
Diaphragmatic injury	35.10	17.55	7	3899	123	29570498
Coronary artery disease	33.64	17.55	35	3871	44155	29526466
Autoimmune haemolytic anaemia	29.67	17.55	13	3893	3835	29566786
Implant site infection	29.26	17.55	9	3897	977	29569644
Marrow hyperplasia	29.22	17.55	9	3897	982	29569639
Psoriatic arthropathy	28.64	17.55	20	3886	14671	29555950
Granuloma	28.07	17.55	11	3895	2453	29568168
Pain	26.42	17.55	65	3841	171367	29399254
Granulomatous liver disease	25.16	17.55	7	3899	535	29570086
Mycobacterial infection	23.68	17.55	9	3897	1847	29568774
Intervertebral disc degeneration	22.89	17.55	12	3894	5252	29565369
Psoriasis	21.82	17.55	24	3882	32203	29538418
Drug abuser	20.37	17.55	10	3896	3817	29566804
Renal atrophy	20.36	17.55	7	3899	1080	29569541
Upper gastrointestinal haemorrhage	19.68	17.55	19	3887	21895	29548726
Ankylosing spondylitis	19.54	17.55	10	3896	4166	29566455
Pulmonary granuloma	19.00	17.55	7	3899	1319	29569302
Injury	18.03	17.55	17	3889	19029	29551592

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug hypersensitivity	100.44	13.59	156	10374	237659	64250543
Coronary artery disease	42.73	13.59	51	10479	60382	64427820
Splenic embolism	42.16	13.59	9	10521	179	64488023
Sideroblastic anaemia	40.09	13.59	9	10521	228	64487974
Retinopathy	38.51	13.59	16	10514	3349	64484853
Vitamin B1 decreased	37.26	13.59	9	10521	316	64487886
Depression	35.93	13.59	87	10443	183204	64304998
Diaphragmatic injury	33.61	13.59	7	10523	123	64488079
Emotional distress	26.43	13.59	31	10499	36007	64452195
Anxiety	25.63	13.59	82	10448	202567	64285635
Drug abuser	24.65	13.59	14	10516	5794	64482408
Off label use	24.61	13.59	41	10489	632765	63855437
Marrow hyperplasia	24.39	13.59	9	10521	1375	64486827
Injury	23.91	13.59	37	10493	55955	64432247
Implant site infection	22.75	13.59	9	10521	1660	64486542
Autoimmune haemolytic anaemia	22.09	13.59	14	10516	7062	64481140
Rubella	21.65	13.59	5	10525	144	64488058
Cerebrovascular accident	20.50	13.59	59	10471	137524	64350678
Febrile neutropenia	18.53	13.59	4	10526	187653	64300549
Drug withdrawal syndrome	18.26	13.59	24	10506	31267	64456935
Granulomatous liver disease	18.11	13.59	7	10523	1215	64486987
Gastrooesophageal reflux disease	17.93	13.59	41	10489	83102	64405100
Mycobacterial infection	17.73	13.59	9	10521	2979	64485223
Myocardial infarction	17.35	13.59	63	10467	165758	64322444
Pain	16.55	13.59	150	10380	553361	63934841
Renal atrophy	16.02	13.59	7	10523	1657	64486545
Granuloma	15.58	13.59	11	10519	6630	64481572
Neutropenia	15.52	13.59	10	10520	239614	64248588
Pulmonary granuloma	15.35	13.59	7	10523	1832	64486370
Psoriasis	15.07	13.59	35	10495	71668	64416534
Blood cholesterol increased	14.67	13.59	28	10502	50038	64438164
Drug dependence	14.20	13.59	22	10508	33290	64454912
Hypertension	13.97	13.59	81	10449	259180	64229022

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	M01AX01	MUSCULO-SKELETAL SYSTEM ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS Other antiinflammatory and antirheumatic agents, non-steroids
FDA CS	M0001335	Anti-Inflammatory Agents, Non-Steroidal
FDA MoA	N0000000160	Cyclooxygenase Inhibitors
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D000893	Anti-Inflammatory Agents
MeSH PA	D000894	Anti-Inflammatory Agents, Non-Steroidal
MeSH PA	D018501	Antirheumatic Agents
MeSH PA	D052246	Cyclooxygenase 2 Inhibitors
MeSH PA	D016861	Cyclooxygenase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35475	non-steroidal anti-inflammatory agent
CHEBI has role	CHEBI:50266	Prodrugs
CHEBI has role	CHEBI:50629	COX-2 inhibitor
FDA EPC	N0000175722	Nonsteroidal Anti-inflammatory Drug

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Rheumatoid arthritis	indication	69896004	DOID:7148
Osteoarthritis	indication	396275006
Ankylosing spondylitis	off-label use	9631008	DOID:7147
Juvenile rheumatoid arthritis	off-label use	410795001
Alcoholism	contraindication	7200002
Peptic ulcer	contraindication	13200003	DOID:750
Acute gastric ulcer with perforation	contraindication	19850005
Myocardial infarction	contraindication	22298006	DOID:5844
Hypertensive disorder	contraindication	38341003	DOID:10763
Gastrointestinal ulcer	contraindication	40845000
Disorder of cardiovascular system	contraindication	49601007	DOID:1287
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Gastrointestinal hemorrhage	contraindication	74474003
Kidney disease	contraindication	90708001	DOID:557
Coronary artery bypass graft	contraindication	232717009
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Cardiovascular event risk	contraindication	395112001
Smokes tobacco daily	contraindication	449868002

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Prostaglandin G/H synthase 2	Enzyme	P35354	PGH2_HUMAN	INHIBITOR			CHEMBL	CHEMBL
Prostaglandin G/H synthase 1	Enzyme	P23219	PGH1_HUMAN		IC50	3.34	WOMBAT-PK
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	5.73	DRUG MATRIX
Cytochrome P450 1A2	Enzyme	P05177	CP1A2_HUMAN		IC50	5.30	DRUG MATRIX
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		IC50	6.00	DRUG MATRIX

External reference:

ID	Source
4020284	VUID
N0000148161	NUI
D00425	KEGG_DRUG
4020284	VANDF
C0068334	UMLSCUI
CHEBI:76252	CHEBI
NBO	PDB_CHEM_ID
CHEMBL1070	ChEMBL_ID
DB00461	DRUGBANK_ID
D000077430	MESH_DESCRIPTOR_UI
4409	PUBCHEM_CID
4855	INN_ID
7245	IUPHAR_LIGAND_ID
LW0TIW155Z	UNII
31448	RXNORM
41877	MMSL
5142	MMSL
d00310	MMSL
003622	NDDF
108508000	SNOMEDCT_US
386859000	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1657	TABLET, FILM COATED	500 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1658	TABLET, FILM COATED	750 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0145	TABLET	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0185-0146	TABLET	750 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5843	TABLET, FILM COATED	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0440-5844	TABLET, FILM COATED	750 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3670	TABLET, FILM COATED	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3670	TABLET, FILM COATED	500 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3671	TABLET, FILM COATED	750 mg	ORAL	ANDA	26 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3671	TABLET, FILM COATED	750 mg	ORAL	ANDA	26 sections
Nabumetone 500 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0722-7076	TABLET, FILM COATED	500 mg	ORAL	ANDA	28 sections
Nabumetone 750 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0722-7077	TABLET, FILM COATED	750 mg	ORAL	ANDA	28 sections
Nabumetone 1000 mg	HUMAN PRESCRIPTION DRUG LABEL	1	0722-7078	TABLET, FILM COATED	1000 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	10544-003	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	10544-120	TABLET, FILM COATED	500 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	10544-271	TABLET, FILM COATED	750 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	10544-273	TABLET	500 mg	ORAL	ANDA	25 sections
RELAFEN DS	HUMAN PRESCRIPTION DRUG LABEL	1	15370-170	TABLET	1000 mg	ORAL	ANDA	30 sections
RELAFEN DS	HUMAN PRESCRIPTION DRUG LABEL	1	15370-170	TABLET	1000 mg	ORAL	ANDA	30 sections
NABUMETONE	HUMAN PRESCRIPTION DRUG LABEL	1	16590-160	TABLET	750 mg	ORAL	ANDA	25 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	21695-230	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	21695-231	TABLET, FILM COATED	750 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	33261-077	TABLET, FILM COATED	500 mg	ORAL	ANDA	28 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	33261-078	TABLET, FILM COATED	750 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	33358-251	TABLET, FILM COATED	500 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	33358-252	TABLET, FILM COATED	750 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	35356-687	TABLET, FILM COATED	500 mg	ORAL	ANDA	28 sections
NABUMETONE	HUMAN PRESCRIPTION DRUG LABEL	1	42549-523	TABLET, FILM COATED	500 mg	ORAL	ANDA	23 sections
NABUMETONE	HUMAN PRESCRIPTION DRUG LABEL	1	42549-648	TABLET, FILM COATED	750 mg	ORAL	ANDA	29 sections
Nabumetone	HUMAN PRESCRIPTION DRUG LABEL	1	43063-859	TABLET, FILM COATED	750 mg	ORAL	ANDA	28 sections